82 results
424B5
WVE
Wave Life Sciences Ltd.
8 Dec 23
Prospectus supplement for primary offering
6:06am
methods based on decades of improvements, as well as established regulatory, access, and reimbursement pathways.
Our approach is based … based on decades of improvements, as well as established regulatory, access and reimbursement pathways.
Our approach is based on the scientific
8-K
EX-1.1
WVE
Wave Life Sciences Ltd.
7 Dec 23
Wave Life Sciences Prices $100 Million Public Offering of Ordinary Shares
9:26pm
10 shall at all times be effective and shall survive such termination.
Section 7. Reimbursement of Underwriters’ Expenses. If this Agreement
424B5
ezkazbpbowwoh
6 Dec 23
Prospectus supplement for primary offering
4:13pm
8-K
abt4ife
26 Sep 22
Departure of Directors or Certain Officers
4:15pm
8-K
EX-1.1
6xuy42
14 Jun 22
Wave Life Sciences Announces Pricing of $70.0 Million Underwritten Offering
9:32am
424B5
1gzy 74wy7
14 Jun 22
Prospectus supplement for primary offering
9:24am
8-K
EX-99.2
pmkbu 3dg
12 May 22
Wave Life Sciences Reports First Quarter 2022 Financial Results and Provides Business Update
7:40am